Sleep Agents Update Warnings As FDA Seeks Further Study Of “Complex” AEs
Executive Summary
Questions about the safety of drugs in the sedative-hypnotic class could warrant additional clinical trials to further evaluate the complex sleep-related behaviors associated with the drugs, FDA said in announcing stronger warnings for the class March 14
You may also be interested in...
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Transcept Gains Long-Delayed Approval Of Intermezzo
Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.